MedTrace Logo

Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD Test; A Prospective Observational Multicenter Study (The MRD Molecular Surveillance Study)

NCT07475923 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2026-04-16

No results posted yet for this study

Summary

To learn about changes in ctDNA during the diagnosis, treatment, and post-treatment surveillance of EBC.

Conditions

  • Molecular Surveillance
  • Breast Cancer
  • ctDNA
  • MRD
  • Observational Study

Interventions

DIAGNOSTIC_TEST

Blood draw for the laboratory assessment

Blood will be drawn up to every cycle during neoadjuvant treatment

DRUG

Neoadjuvant treatment

Given by IV

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Carlos H Barcenas, MD · M.D. Anderson Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-09
Primary Completion
2026-04-09
Completion
2026-04-09

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07475923 on ClinicalTrials.gov